Figure 1
Association of low PRMT1 expression with poor prognosis in non-MYCN-amplified neuroblastoma patients and establishment of stable PRMT1-knockdown (PRMT1-KD) in a non-MYCN-amplified neuroblastoma cell line SK-N-SH. (A) Kaplan-Meier analysis of relapse-free survival for the Seeger dataset with 102 patients with non-MYCN-amplified neuroblastoma. The graph was downloaded from R2 genomics analysis and visualization platform (http://r2.amc.nl). The default “scan” modus was used to determine the cutoffof high and low expression. Patients with high PRMT1 expression were highlighted in blue, whereas patients with low PRMT1 expression were highlighted in red. (B) Cell extracts (20 μg of protein) from control vector-infected, PRMT1 A1 or B1 shRNA-infected SK-N-SH cells were immunoblotted with anti-PRMT1. Detection by anti-β-actin was used as a loading control. (C) Cell extracts (20 μg of protein) were immunoblotted with asymmetric dimethylarginine-specific antibody ASYM24 (left) and ADMA (right). The immunoblots shown are the representatives of at least three independent experiments. (D) Extracts from non-infected, control vector-infected, PRMT1 A1 or B1 shRNA-infected SK-N-SH cells, and mouse brain (50 μg of protein) were immunoblotted with anti-MYCN.
